Radiotherapy | Nano Publications

2017 – Abstract – 13th Journées cancéropole GSO – HfO2 nanoparticles in solid tumors

Clinical Data NBTXR3, Congress Abstracts, Head & Neck, Liver, Rectum, STS

The enclosed abstract was presented at the 13th Journées cancéropole Grand Sud-Ouest at Poitiers. The abstract Hafnium oxide nanoparticles as an emergent promising treatment for solid tumors describes how hafnium oxide nanoparticles were designed at the nanoscale in the form of crystalline 50nm-particles to efficiently absorb ionizing radiation and increase the radiation dose deposited – “hot spots” of energy deposit – from within the tumor cells for efficient cell killing. […]

2017 – Abstract – THNO – NBTXR3 in combination with IMRT in patients with locally advanced HNSCC

Clinical Data NBTXR3, Congress Abstracts, Head & Neck

At the 2017 THNO in Nice, France, prof. C. Le Tourneau presented preliminary results of NBTXR3 in patients suffering from HNSCC. The treatment was associated with a positive safety profile, and preliminary effiacy evaluation, the local Complete Response rate is 83 % (dose level15% and 22%), with a duration of response of 22 months. […]

2017 – Abstract – CTOS – NBTXR3 induces antitumoral immune response in human STS

Clinical Data NBTXR3, Congress Abstracts, STS

The enclosed abstract was presented at the “2017 Connective Tissue Oncology Society Annual Meeting (CTOS), Maui, Hawaii”. The abstract “NBTXR3 Treatment Induces Antitumoral Immune Response in Human Soft Tissue Sarcoma” describes how NBTXR3 activated by RT triggers an enhanced adaptive immune response and contributes to transform “cold” tumor into “hot” tumor.

2017 – Abstract SITC Conference Maryland – Clinical

Clinical Data NBTXR3, Congress Abstracts, STS

Soft tissue sarcoma (STS) is a large and heterogeneous group of malignant mesenchymal neoplasms characterized by a strong tendency toward local recurrence and metastatic spreading. Consistently, the immune microenvironment in sarcomas is highly variable. A new class of material with high electron density, hafnium oxide, was designed at the nanoscale to efficiently absorb ionizing radiation […]

2017 – Abstract – 35th CFS – Hafnium Oxide Nanoparticles: An Emergent Promising Treatment for Solid Tumors

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3

Hafnium oxide nanoparticles: an emergent promising treatment for solid tumors To improve tumor response, radiotherapy (RT) has been combined with chemical agents, radiosensitizers and monoclonal antibodies. However, the complexity of these associations in terms of pharmacology, local control, clinical outcome benefits or patient quality of life underlines the need for the development of new therapeutic approaches. […]

2017 – Abstract Conference Immunotherapy Radiotherapy Combinations NYC

Congress Abstracts, In Vitro, In Vitro in Vivo NBTXR3, In Vivo

Hafnium oxide, an electron-dense material, was designed at the nanoscale to increase the radiation dose deposited from within the cancer cells: “Hot spot” of energy deposit where the nanoparticles are when exposed to radiation therapy (RT). Preclinical studies have demonstrated increase of cancer cells killing in vitro and marked antitumor efficacy in vivo with presence of these nanoparticles […]

2017 – AACR-EORTC-NCI Monte Carlo Calculation

Congress Abstracts, Miscellaneous

Today, more than half of all cancer patients receive radiotherapy as part of their treatment. However, radiotherapy efficacy is often limited by healthy tissues toxicity and needs to be optimized. One relevant solution is to increase the radiation dose deposition from within the tumor cells. […]

2017 – Abstract SITC Conference Maryland – Non Clinical

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

2017 – Abstract AACR-EORTC-NCI

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Between 70 to 90% of patient have "cold" tumors, i.e. devoid or poorly infiltrated by immune cells, rendering inoperative their treatment by immune checkpoint inhibitors. To allow these patients to benefit from these therapies, it is fundamental to prime an antitumor immune response. […]

2017 – Immunotherapy Workshop

Congress Abstracts, In Vitro in Vivo NBTXR3, In Vivo

Radiotherapy (RT) has proven its ability to function like an in-situ vaccine, showing potential for successful combination with immunotherapeutic agents. Hafnium oxide nanoparticle (HfO2-NP), undergoing clinical trials for enhancing RT, was designed as high electron density material at the nanoscale. HfO2-NPs are taken up by cancer cells and, when exposed to RT, locally increase the radiation dose deposit, triggering more cancer cells death when compared to RT. We hypothesized that HfO2-NP+RT could trigger an enhanced immune response when compared to RT, both in preclinical and clinical settings.